Author Title [ Type(Desc)] Year
Filters: Author is Bhatia, Monica  [Clear All Filters]
Journal Article
Offer K, Kolb M, Jin Z, Bhatia M, Kung AL, George D, Garvin JH, Robinson C, Sosna J, Karamehmet E, et al. The Efficacy of Tacrolimus/Mycophenolate Mofetil as Acute Graft-Versus-Host-Disease Prophylaxis and the Impact of Sub Therapeutic Tacrolimus Levels in Children Following Matched Sibling Donor Allogeneic Hematopoietic Cell Transplantation. Biol Blood Marrow Transplant. 2014.
Shah NC, Bhoopatiraju S, Abraham A, Anderson E, Andreansky M, Bhatia M, Chaudhury S, Cuvelier GDE, Godder K, Grimley M, et al. Granulocyte Colony-Stimulating Factor is Safe and Well Tolerated following Allogeneic Transplantation in Patients with Sickle Cell Disease. Transplant Cell Ther. 2021.
Tanhehco YC, Bhatia M. Hematopoietic stem cell transplantation and cellular therapy in sickle cell disease: where are we now?. Curr Opin Hematol. 2019.
Ferrua F, Galimberti S, Courteille V, Slatter MAnne, Booth C, Moshous D, Neven B, Blanche S, Laberko A, Shcherbina A, et al. Hematopoietic stem cell transplantation for CD40 ligand deficiency: results from an EBMT/ESID-IEWP-SCETIDE-PIDTC Study. J Allergy Clin Immunol. 2019.
Nickel RSheppard, Seashore E, Lane PA, Alazraki AL, Horan JT, Bhatia M, Haight AE. Improved Splenic Function After Hematopoietic Stem Cell Transplant for Sickle Cell Disease. Pediatr Blood Cancer. 2016.
Davis L, Yao Y, Jin Z, Moscoso S, Neunert C, Broglie L, Hall M, Bhatia M, George D, Garvin JH, et al. Length of Stay and Health Care Utilization Among Pediatric Autologous Hematopoietic Cell Transplantation Recipients. Transplant Cell Ther. 2021.
Broglie L, Ruiz J, Jin Z, Kahn JM, Bhatia M, George D, Garvin J, Satwani P. Limitations of Applying the Hematopoietic Cell Transplantation Comorbidity Index in Pediatric Patients Receiving Allogeneic Hematopoietic Cell Transplantation. Biol Blood Marrow Transplant. 2020.
Subburaj D, Ng B, Kariminia A, Abdossamadi S, Lauener M, Nemecek ER, Rozmus J, Kharbanda S, Kitko CL, Lewis VAnthony, et al. Metabolomic Identification of Alpha-Ketoglutaric Acid Elevation in Pediatric Chronic Graft-versus-Host Disease. Blood. 2021.
Jacobsohn DA, Loken MR, Fei M, Adams A, Brodersen LEidenschin, Logan BR, Ahn KWoo, Shaw BE, Kletzel M, Olszewski M, et al. Outcomes of measurable residual disease in pediatric acute myeloid leukemia pre- and post-hematopoietic stem cell transplant: validation of difference from normal flow cytometry with chimerism studies and Wilms tumor 1 gene expression. Biol Blood Marrow Transplant. 2018.
Zahler S, Bhatia M, Ricci A, Roy S, Morris E, Harrison L, van de Ven C, Fabricatore S, Wolownik K, Cooney-Qualter E, et al. A Phase I Study of Reduced Intensity Conditioning and Allogeneic Stem Cell Transplantation Followed by Dose Escalation of Targeted Consolidation Immunotherapy with Gemtuzumab Ozogamicin in Children and Adolescents with CD33+ Acute Myeloid Leukemia. Biol Blood Marrow Transplant. 2016.
McGuinn C, Geyer MB, Jin Z, Garvin JH, Satwani P, M Bradley B, Bhatia M, George D, Duffy D, Morris E, et al. Pilot trial of risk-adapted cyclophosphamide intensity based conditioning and HLA matched sibling and unrelated cord blood stem cell transplantation in newly diagnosed pediatric and adolescent recipients with acquired severe aplastic anemia. Pediatr Blood Cancer. 2014.